CONGRESS ABSTRACT

Background: Recent meta analyzes have highlighted the key role of oxLDL in cardiovascular risk in patients with/without cancer through the stimulation of pro-inflammatory signaling. GLP-1 receptor agonists, like semaglutide, have shown cardiorenal benefits in patients with/without diabetes, proposing themselves as a new cardioprotective strategy in a broad patient setting. PCSK9i inclisiran exerts cardiovascular benefits through intrahepatic and extrahepatic functions, involving myocardial tissue. High risk patients with hyperlipidemia and treated with anthracyclines need new pharmacological strategies to reduce the magnitude of CTRCD and reduce overall mortality.   Purpose: We report for the first time the results of the use of combination therapy with a glucagon-like peptide-1 receptor agonist and PCSK9i for the primary prevention of anthracyline-mediated cardiotoxicity. Methods:  Human cardiomyocytes (HFC cell line) were exposed to subclinical concentration of doxorubicin, (200 nM), alone or in combination with inclisiran (100 nM) and or semaglutide (100 nM) for 48h under exposure to 200 μg/ml oxLDL (hyperlipidemia). After the incubation period, we performed the following tests: determination of cell viability, study of lipid peroxidation (quantifying cellular Malondialdehyde and 4-hydroxynonenal), intracellular Ca2+ homeostasis. Moreover, pro-inflammatory studied were also performed (activation of NLRP3; expression of TLR4/MyD88; mTORC1 Fox01/3a; transcriptional activation of p65/NF-κB and expression of cytokines involved in cardiotoxicity (IL-1α, IL-1β, IL-2, IL-4, IL-6, IL-10, IL-12, IL17-α, IFN-γ, TNF-α, G-CSF, GM-CSF). Results: Inclisiran and semaglutide co-incubated with doxorubicin exerts synergistic and significant cardioprotective effects,compared to monotherapy regimens, enhancing cell viability of 74,7-88,4 % compared to doxorubicin-oxLDL treated cells (p<0,01 for all). Significant reductions of oxidative stress, ferroptosis and intracellular levels of NLRP-3, MyD88, p65NF-KB, IL-1α, IL-1β, IL-6, IL-12, IL17-α, TNF-α, G-CSF were seen in semaglutide/inclisiran group vs only doxo groups under oxLDL exposure (p<0.05); contrary, IL-10 was significantly increased. Conclusion: For the first time, combination therapy with Semaglutide and PCSK9i inclisiran was effective and superior, compared to monotherapy, to reduce anthracycline-mediated cardiotoxicity through different signalling pathways.